On Friday, NPR had a very interesting and inspiring interview with Dr. Siddhartha Mukherjee, oncologist at Columbia University in New York. He has written a new article called The Improvisational Oncologist in this week’s Sunday Magazine of the New York Times. In this article, he focuses on the emergence of immuno-oncology in daily practice, and how to use it optimally within the complexity of managing cancer.

Dr. Mukherjee describes – what I have called it many times – the ‘modern day alchemist’, often changing the treatment approach, trying something radically new in the quest for the ‘holy grail’: curing a patient’s cancer. With modern day scientific advances, the management of cancer has become infinitely more complex than when I was in med school. It has also become much more interesting and challenging at the same time, offering vastly improved outcomes and thereby hope to patients.

It is stories like these, and the inspiring work of 95,000+ cancer treaters we collaborate with at MDOutlook that keeps our team motivated on our quest to advance cancer management by providing oncology intelligence.

Thank you to all, and not in the least our team, to move this forward!
Jan Heybroek
President, MDOutlook

MDOutlook® is pleased to share excerpts from the most recent MDOutlook’s OncoPoll™: Clinical Impact of Recent Data Announcements in the treatment of Acute Myeloid Leukemia (AML).

This research is the newest in a long line of impact studies following major data announcements in cancer. MDOutlook has covered the oncology space since 2008 in more depth and with more focus than most disease intelligence organizations.

This report is based on an on-line survey of US and European oncologists focused on AML.

Key Conclusions: Immediate Impact of New AML Data on Clinical Practice:
• Physicians believe midostaurin will have the greatest importance to their clinical practice with AML, and sorafenib and gilteritinib having slightly less clinical importance
• Midostaurin would be the dominant FLT3 inhibitor integrated into induction therapies for FLT3+ AML, while sorafenib is expected to be integrated into induction protocols as well
• For FLT3+ AML post-transplant maintenance therapy, midostaurin would be widely accepted, but sorafenib would be used by less than half of physician under these circumstances

Access the full complimentary AML OncoPoll report through the link. And contact us to discuss your oncology intelligence needs.

Submitted by Dr. Robert Stephan, Vice President, Research and Physician Society, and Jan Heybroek, President of MDOutlook. All Rights Reserved ©2016. All registered trademarks are the property of their respective owners.

Recently announced advances in the treatment of Multiple Myeloma (MM), for both newly diagnosed and relapsed / refractory patients, have been quickly embraced by oncologists globally.

MDOutlook are pleased to share complimentary highlights from the most recent MDOutlook OncoPoll™: Clinical Impact of Recent Data Announcements in the treatment of Multiple Myeloma. This research is based on an on-line survey of US and European oncologists actively managing MM patients. Access the highlights here. Copies of the full report are available upon request.

If you have any questions or feedback, or want to discuss how MDOutlook can provide deep, customized insight to your specific oncology needs, please let us know.

MDOutlook is pleased to release the third report on the clinical impact of new data presented at ASCO and EHA 2015. This report includes analyses from 2 studies in hematologic malignancies involving more than 150 oncologists and hematologists with identified focus on Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM).

Our MD/PhD Disease Analyst Team reports:
CLL

• Both the HELIOS and Complement 2 clinical trials will impact the CLL treatment landscape
  – Ibrutinib usage is expected to rise by 50% to 110% across all CLL subgroups in the next 6 months
  – Anti-CD20 mAb usage in CLL is slowly shifting from 1st generation rituximab to 2nd / 3rd generation ofatuzumab and obinutuzumab
• Physicians have very high expectations for the BCL-2 Inhibitor venetoclax in CLL
  – The new PI3K inhibitors duvelisib and TGR-1202 are also positively viewed

Multiple Myeloma

• The immune-oncology revolution has come to multiple myeloma with 2 new monoclonal antibodies: the anti-CS1 mAb elotuzumab and the anti-CD38 mAb daratumumab
• Virtually all oncologists would use elotuzumab in at least some of their relapsed / refractory myeloma patients if it were commercially available today
  – 40% of respondents reported they would use it in 60% or more of their patients
  – Overall, ~50-60% of relapsed / refractory myeloma patients would receive it as treatment
• Carfilzomib (Kd) is expected to become the preferred proteasome inhibitor over bortezomib (Vd) in the therapy of relapsed MM

Download your complimentary copy of the MDOutlook 2015 ASCO-EHA Syndicated CLL and MM OncoPoll Report  through the link.

MDOutlook continues its commitment to all stakeholders involved in the management of cancer to provide meaningful, timely and relevant insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community. This is MDoutlook’s 8th consecutive year of syndicated research analyzing new data presented at large cancer meetings, and consists of more than 40 reports since 2008.

MDOutlook is disease intelligence redefined. Governed by top ThoughtLeaders and driven by in-house MD and PhD medical experts, MDOutlook® is powered by a proprietary, global cloud-based disease intelligence platform accessing 1M+ multi-disciplinary treaters of complex diseases, including cancer, hematology, auto-immune diseases.

Email or phone (+1.404.496.4136 / 888.3outlook) to discuss how MDOutlook can answer your disease intelligence needs.

MDOutlook proudly presents the second study on the clinical impact of new data presented at ASCO 2015. This OncoPoll™ includes analyses from 2 studies in Gastrointestinal Cancers involving more than 160 oncologists.

Our MD/PhD research team reports the following analysis highlights:
Non-CRC GI Cancers

• Anti-PD-1 antibodies are expected to have a large impact for selected patients with Gastric, Esophageal and Hepatocellular Cancers
• At current drug costs, only average value is placed on these agents in GI cancers (lower than what is seen for NSCLC)
• 75% of the respondents expect the PEGH20 addition to have intermediate or high clinical impact on the treatment of pancreatic cancer
• Regorafenib will be widely used in advanced G/GEJ cancers upon regulatory approval

Metastatic Colorectal Cancer

• The immune checkpoint inhibitors (anti-PD-1/PD-L1) are going to have a very significant impact on the treatment landscape for MMR-deficient mCRC
  – Over a quarter of mCRC patients with this deficiency are expected to receive this treatment almost immediately
  – Most mCRC patients will now be tested for an MMR deficiency
• At today’s prices, physicians see good value in using the anti-PD-1/PD-L1 antibodies for mCRC
• Combining BRAF+/-MEK inhibitors with anti-EGFR antibodies is initially seen to have only a limited impact on the treatment of BRAF-mutated CRC

Download your complimentary copy of the MDOutlook 2015 ASCO Syndicated GI Cancers OncoPoll here.

MDOutlook continues its commitment to all stakeholders involved in the management of cancer to provide meaningful, timely and relevant insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community.

MDOutlook is disease intelligence redefined. Governed by top ThoughtLeaders and driven by in-house MD and PhD medical experts, MDOutlook® is powered by a proprietary, global cloud-based disease intelligence platform accessing 1M+ multi-disciplinary treaters of complex diseases, including cancer, hematology, auto-immune diseases.

Email or phone (+1.404.496.4136 / 888.3outlook) to discuss how MDOutlook can answer your disease intelligence needs.

MDOutlook celebrates its 8th consecutive year of syndicated research gauging the clinical impact of new data presented at ASCO 2015. Building on over 30 analyses since 2008, MDOutlook today releases the first analysis in a new series covering solid and liquid tumors.

This OncoPoll™ focuses on the continued evolution of targeted therapy, and especially on the clinical impact of exciting new updates for Immune Checkpoint Inhibitors. Our most recent research from 125 global oncologists managing NSCLC patients uncovers that:

• For cases of NSCLC without driver mutations, treatment with the anti-PD-1/PD-L1 antibodies is expected to become the main 2nd line treatment option
• These anti-PD-1/PD-L1 antibodies WILL be included in the treatment of ALK+ or EGFR-mutated NSCLC, albeit in 1 later line of therapy (primarily starting in 3rd line)
• Combining the anti-PD-1/PD-L1 antibodies with the anti-CTLA-4 antibody ipilimumab is seen as a promising approach that will further impact treatment paradigms in the future
• Even at today’s prices, physicians see good value in using the anti-PD-1/PD-L1 antibodies for NSCLC

Download your complimentary copy of the MDOutlook 2015 ASCO Syndicated NSCLC OncoPoll through the link.

MDOutlook continues its commitment to the cancer community to provide meaningful, timely and relevant insight. As in previous years, we work with Oncology Business Review to share this important research widely.

MDOutlook is disease intelligence redefined. Governed by top ThoughtLeaders and driven by in-house MD and PhD medical experts, MDOutlook® is powered by a proprietary, global cloud-based disease intelligence platform accessing 1M+ multi-disciplinary treaters of complex diseases, including cancer, hematology, auto-immune diseases.

Email or phone (+1.404.496.4136 / 888.3outlook) to discuss how MDOutlook can answer your disease intelligence needs.